The FDA approval of Pfizer and BioNTech's LP.8.1 COVID-19 vaccine on August 27, 2025, is a significant event for the 2025-2026 vaccination season, enabling the companies to supply an updated vaccine formulation. This approval ensures Pfizer's continued participation in the evolving seasonal COVID-19 vaccine market.1
While specific revenue projections solely attributable to the LP.8.1 vaccine are not explicitly delineated in available public disclosures, its impact is integrated into the broader financial outlook for both Pfizer and its partner, BioNTech.
Key points regarding the revenue impact include:
- Overall Revenue Projections for Pfizer (PFE): Analyst estimates compiled by Fintel project Pfizer's total annual revenue for 2025 to be approximately $67.14 billion, based on 13 analysts. For the fourth quarter of 2025, the average quarterly revenue estimate stands at $18.26 billion from 3 analysts. Looking ahead, 2026 annual revenue is estimated at $66.53 billion by 12 analysts.2
- BioNTech's Contribution: BioNTech, as Pfizer's partner, reaffirmed its 2025 total revenue guidance in the range of €1.7 billion to €2.2 billion. This guidance incorporates its share of COVID-19 vaccine sales, with revenue generation expected to be concentrated primarily in the last three to four months of the year, aligning with the seasonal vaccination period.3
- Market Context: The COVID-19 vaccine market is transitioning from a pandemic-driven model to a more seasonal commercial market. This shift has led to lower sales volumes in some international markets as advance purchase agreements phase out, a trend also observed by other vaccine manufacturers.4 BioNTech's guidance assumes relatively stable vaccination rates, pricing, and market share compared to 2024.5
In essence, the LP.8.1 vaccine approval is a factor within Pfizer's existing revenue streams, contributing to the overall financial performance rather than representing a new, isolated revenue driver. The ability to offer an updated vaccine formulation helps maintain market share in a competitive and evolving landscape.
